U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1925
    -0.0054 (-0.45%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3827
    -0.0067 (-0.48%)
     
  • USD/JPY

    108.2450
    +0.2690 (+0.25%)
     
  • BTC-USD

    48,958.54
    +631.27 (+1.31%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

New Strong Sell Stocks for January 20th

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Ituran Location and Control Ltd. ITRN provides location-based services and wireless communications products. The Zacks Consensus Estimate for its current year earnings has been revised nearly 6% downward over the last 30 days.

NGM Biopharmaceuticals, Inc. NGM is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 4.8% downward over the last 30 days.

Hilton Worldwide Holdings Inc. HLT is a hospitality company that owns, leases, manages, develops, and franchises hotels and resorts. The Zacks Consensus Estimate for its current year earnings has been revised 5.6% downward over the last 30 days.

Aramark ARMK provides food, facilities, and uniform services to education, healthcare, business and industry, sports, leisure, and corrections client. The Zacks Consensus Estimate for its current year earnings has been revised 4.4% downward over the last 30 days.

ProQR Therapeutics N.V. PRQR is a biopharmaceutical company that engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. The Zacks Consensus Estimate for its current year earnings has been revised nearly 1% downward over the last 30 days.

View the entire Zacks Rank #5 List.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
NGM Biopharmaceuticals, Inc. (NGM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research